IngredientesCoenzyme A (CoA) is an essential cofactor in all living organisms. The name itself carries a precise historical meaning: the "A" stands for acetyl, with CoA's major role being to transfer two-carbon units in the form of acetyl between various biological molecules. The molecule is also referred to in its free, unbound state as CoASH or HSCoA, denoting the presence of the reactive free thiol group. A molecule of coenzyme A carrying an acyl group is referred to as acyl-CoA.
Coenzyme A is a complex molecule with a molecular formula of C21H36N7O16P3S and a molecular weight of approximately 767.5 Da in its free form. The structure of CoA includes three major components: an adenine nucleotide, pantothenate, and β-mercaptoethylamine (cysteamine). This is consistent with earlier descriptions noting that coenzyme A has a complex structure consisting of an adenosine triphosphate, a pantothenic acid (a B-vitamin), and cysteamine.
The functional portion of this complex molecule is the sulfhydryl (–SH) group at one end; the coenzyme is often identified as CoA–SH. Since coenzyme A is, in chemical terms, a thiol, it can react with carboxylic acids to form thioesters, thus functioning as an acyl group carrier. The presence of a highly reactive thiol group and a nucleotide moiety offers a diversity of chemical reactions and regulatory interactions; CoA employs them to activate carbonyl-containing molecules and to produce various thioester derivatives — e.g., acetyl-CoA, malonyl-CoA, and 3-hydroxy-3-methylglutaryl-CoA — which have well-established roles in cellular metabolism, production of neurotransmitters, and the regulation of gene expression.
CoA occurs in all living cells as an essential component in the metabolism of carbohydrates, fats, and certain amino acids. Because it is present in virtually every tissue and organ, it does not have a single "botanical" source in the way that a plant-derived supplement does. However, humans have lost the ability to synthesize water-soluble vitamins; pantothenate can be efficiently released from the (acyl-)CoA present in food and from the gut microbiome, before being absorbed in the intestine and distributed through the bloodstream to all organs. In dietary terms, CoA precursors are found in all pantothenic acid-containing foods — broadly, meat, poultry, fish, whole grains, and vegetables.
Importantly, CoA itself cannot diffuse across membranes, and each cell needs to take up pantothenate (Pan) to synthesize its own CoA. This has direct implications for oral supplementation, discussed in the evidence section below.
As a dietary supplement or investigational agent, CoA has been prepared and studied in several forms. The primary commercially available preparation used in the Chinese clinical trials described below is an oral capsule standardized in units (U) — most commonly 200 U/d or 400 U/d dosing regimens. In a previous multicenter study conducted in 2008, oral CoA 400 U/d monotherapy effectively lowered serum triglyceride levels in hypertriglyceridemia patients without increasing adverse effects when compared with placebo. Related compounds used in research and supplementation include pantethine (the disulfide of pantetheine, a CoA catabolite), pantothenic acid (vitamin B5, the direct biosynthetic precursor), and 4′-phosphopantetheine (4′-PPT), an intermediate in the CoA biosynthetic pathway increasingly studied as a therapeutic molecule for CoA-deficiency disorders.
Coenzyme A does not have a "traditional" cultural use in the ethnobotanical sense — its identity as a discrete molecule was unknown until the mid-twentieth century, as it cannot be obtained in purified form from whole foods. Its discovery is entirely a product of modern biochemical research.
In 1945, working with a potent enzyme from pigeon liver extract as an assay system for acetyl transfer in animal tissue, Fritz Lipmann and colleagues at Massachusetts General Hospital discovered Coenzyme A (CoA). Lipmann initially intended to study acetyl transfer in animals, and from these experiments he noticed a unique factor that was not present in enzyme extracts but was evident in all organs of the animals. He was able to isolate and purify the factor from pig liver and discovered that its function was related to a coenzyme that was active in choline acetylation.
In the course of his studies on the chemical nature of the active acetate and an intermediate of carbohydrate oxidation, Lipmann discovered the acetyl-carrying coenzyme A. In 1947, he isolated and named the coenzyme, and in 1953, he determined its molecular structure. Its structure was determined during the early 1950s at the Lister Institute, London, together by Lipmann and other workers at Harvard Medical School and Massachusetts General Hospital.
Lipmann subsequently showed that CoA is composed of adenosine 5-phosphate, pantothenic acid, and a sulfhydryl moiety, and that acetyl-CoA is involved in the acetylation of choline, in the synthesis of citrate and acetoacetate, and in pyruvate and fatty acid metabolism. His work on the coenzyme was recognized in 1953 when he shared the Nobel Prize in Physiology or Medicine with Hans Adolf Krebs "for his discovery of co-enzyme A and its importance for intermediary metabolism."
The initial name "coenzyme for acetylation" reflects its primary function before it became known as Coenzyme A, illustrating the evolving knowledge of its roles in metabolism. Through Lipmann's work, it became understood that coenzyme A is related to the B vitamins, and that B vitamins carry out their functions through coenzymatic action in the process of cell metabolism.
The discovery of coenzyme A linked the anaerobic and aerobic phases of cellular respiration, helped quantify the amount of energy production for each glucose molecule an organism consumes, and helped link cellular respiration to other metabolic reaction pathways, such as carbohydrate and protein metabolism.
Pantothenate (vitamin B5) is the key precursor for the biosynthesis of coenzyme A (CoA), a universal and essential cofactor involved in a myriad of metabolic reactions, including the synthesis of phospholipids, the synthesis and degradation of fatty acids, and the operation of the tricarboxylic acid cycle.
The complete biosynthetic pathway proceeds through five enzymatic steps:
Pantothenic acid is a precursor to CoA via this five-step process. The biosynthesis requires pantothenic acid, cysteine, and four equivalents of ATP.
The intracellular levels of CoA are controlled by the balance between synthesis and degradation. In particular, CoA is assembled in five enzymatic steps, starting from the phosphorylation of pantothenate to phosphopantothenate, catalyzed by pantothenate kinase.
The intracellular concentration and distribution in different cellular compartments of CoA and its derivatives are controlled by several extracellular stimuli such as nutrients, hormones, metabolites, and cellular stresses.
Regarding intracellular transport, human mitochondria contain solute carrier family 25 member 42 (SLC25A42), a transporter that exchanges CoA (CoA-SH) for another adenine-containing substrate, including 3′,5′-ADP. In mammalian peroxisomes, there are three members of ATP-binding cassette subfamily D (ABCD1–3) which mediate the transport of acyl-CoA.
Recent research has challenged the longstanding view that cells obtain CoA exclusively through de novo biosynthesis. Evidence suggests that cells can obtain intracellular coenzyme A by pathways in addition to de novo biosynthesis. The consensus had been that intracellular CoA is obtained exclusively by de novo biosynthesis via a universal, conserved five-step pathway in the cell cytosol; however, old and new evidence suggest that cells have several strategies to obtain CoA, with 4′-phosphopantetheine (P-PantSH) serving as a "nexus" metabolite.
Regarding degradation and recycling, the identification and characterization of enzymes that specifically hydrolyze CoA in the mitochondria and peroxisomes supports the conclusion that degradation is an important mechanism to modulate intracellular (acyl-)CoA pools. The evidence indicates that the extracellular and intracellular (acyl-)CoA degradation pathways are regulated in a coordinated and opposite manner by the nutritional state and maximize the changes in the total intracellular CoA levels that support the metabolic switch between fed and fasted states in organs like the liver.
The importance of coenzyme A as a carrier of acyl residues in cell metabolism is well understood. Coenzyme A participates in more than 100 different catabolic and anabolic reactions, including those involved in the metabolism of lipids, carbohydrates, proteins, ethanol, bile acids, and xenobiotics.
CoA's role is essential in the synthesis and oxidation of fatty acids, as well as in the metabolism of carbohydrates and amino acids. The thiol group in CoA forms thioester bonds with acyl groups, enabling their efficient transfer within the cell. These high-energy thioester bonds are crucial for processes such as the citric acid cycle and fatty acid metabolism, where energy transfer is vital.
In its acetyl form, coenzyme A is a highly versatile molecule, serving metabolic functions in both the anabolic and catabolic pathways. Acetyl-CoA is utilized in the post-translational regulation and allosteric regulation of pyruvate dehydrogenase and carboxylase to maintain and support the partition of pyruvate synthesis and degradation.
Coenzyme A assists in transferring fatty acids from the cytoplasm to mitochondria. This process facilitates the production of fatty acids in cells, which are essential in cell membrane structure.
Coenzyme A is a ubiquitous essential cofactor that plays a central role in the metabolism of carboxylic acids, including short- and long-chain fatty acids, as well as carbohydrate and protein. In the metabolic pathway of lipid, CoA participates in fatty acid β-oxidation, promoting triglyceride (TG) catabolism.
Previous research revealed that insufficiency of CoA in vivo influenced fatty acid β-oxidation catabolism and impaired clearance of TG from plasma, which was supposed to be one plausible reason resulting in type IIb and type IV hyperlipoproteinemia. Epidemiological studies showed the prevalence of serum lipids level increased with age, which may be related to the reduction of CoA synthesis in aging individuals.
CoA is involved in a large number of biochemical processes, functioning either as an activator of molecules with carbonyl groups or as a carrier of acyl moieties. Together with its thioester derivatives, it plays a central role in cell metabolism, post-translational modification, and gene expression.
Acetyl-CoA is the most common substrate of acetyltransferase activity, with the transfer of the acetyl moiety to the side chain of lysines in histones representing the first identified and most investigated process. The acetylation of histones extends the connection between CoA levels and the control of cellular functions to the modulation of gene expression. More recent studies showed that proteins other than histones undergo post-translational acetylation, including metabolic enzymes and signaling molecules. The transfer of an acetyl moiety to a protein can affect its function by changing the catalytic activity, the localization, and interaction with other partners.
Cellular acetyl-CoA levels fluctuate according to extracellular nutrient availability and the metabolic state of the cell. The Michaelis constant (Km) of most histone acetyltransferases (HATs) falls within the range of cellular acetyl-CoA concentrations. As a consequence, global levels of histone acetylation are often restricted by availability of acetyl-CoA.
Recent studies revealed a role for CoA in the redox regulation by the S-thiolation of cysteine residues in cellular proteins. This mechanism — termed protein CoAlation — has been characterized in detail:
Using an anti-CoA monoclonal antibody and mass spectrometry, a wide range of cellular proteins were identified that are modified by covalent attachment of CoA to cysteine thiols (CoAlation). Protein CoAlation is a reversible post-translational modification that is induced in mammalian cells and tissues by oxidizing agents and metabolic stress. Many key cellular enzymes were found to be CoAlated in vitro and in vivo in ways that modified their activities. This modification is a widespread post-translational modification which may play an important role in redox regulation under physiological and pathophysiological conditions.
A novel mode of redox regulation involving covalent modification of cellular proteins by CoA — termed protein CoAlation — has been discovered in a collaborative effort of several laboratories.
CoA is also the only source of the phosphopantetheine prosthetic group for enzymes that shuttle intermediates between the active sites of enzymes involved in fatty acid, nonribosomal peptide, and polyketide synthesis. CoA-SH is a substrate in the phosphopantetheinylation process catalyzed by phosphopantetheinyl transferases. As a result of this reaction, 4′-phosphopantetheine is transferred from CoA-SH to a serine residue of proteins such as mitochondrial fatty acid synthase, which results in an inactive apo-synthase being transformed into an active holo-synthase.
The most substantive body of human clinical evidence for CoA supplementation concerns its effects on serum lipids, particularly in the context of hypertriglyceridemia and mixed dyslipidemia. This research has been conducted primarily in Chinese populations.
The aim of one multicenter study was to evaluate the lipid-lowering effects and clinical safety of a natural hypolipidemic compound, coenzyme A (CoA) capsule, in Chinese patients with moderate dyslipidemia. A total of 244 subjects (170 males and 74 females; aged 18–75 years) having moderate dyslipidemia (triglyceride 2.3–6.5 mmol·L−1) were randomly divided into 3 groups, receiving placebo (group A, n=81), CoA 200 U/d (group B, n=79), and CoA 400 U/d (group C, n=84), respectively. This trial, published in the Journal of Clinical Endocrinology & Metabolism in 2013, represents a randomized, double-blind, placebo-controlled multicenter design.
In one 8-week, multicenter, double-blind, randomized, placebo-controlled study, the addition of CoA 400 U/d to an ongoing normal dose of statin was effective in providing additional lowering of TG, TC, LDL-C, and non-HDL-C levels in patients with mixed hyperlipidemia. The combination of CoA and statin was well tolerated. The patients enrolled in this trial were all Chinese subjects, so the results may not be directly extrapolated to other races without international multicenter clinical trial results. Additionally, the underlying mechanisms of the findings could not be completely clarified by the data from this study.
Previous studies showed that intravenous administration of CoA could accelerate TG catabolism and thereby lower TG level by inducing fatty acid oxidation response.
A multicenter, double-blind, double-mimic, randomized clinical trial investigated the lipid-lowering efficacy and safety of coenzyme A (CoA) versus fenofibrate in Chinese patients with moderate dyslipidemia. A total of 417 subjects (aged 18–75 years) diagnosed with moderate dyslipidemia (triglyceride 2.3–6.5 mmol/L) were enrolled.
Studies on animal models provided evidence that supplementation of CoA had normalizing activity on plasma lipids in dyslipidemia. Previous research revealed that insufficiency of CoA in vivo influenced fatty acid β-oxidation catabolism and impaired clearance of TG from plasma, which was supposed to be one plausible reason resulting in type IIb and IV hyperlipoproteinemia.
Evidence strength: The clinical evidence for CoA as a lipid-modifying agent is promising but remains limited. Published trials have been conducted primarily or exclusively in Chinese populations, limiting generalizability. There is insufficient clinical research data to fully support the efficacy and safety of oral CoA when combined with statins in mixed dyslipidemia patients. Independent replication in diverse populations and larger trials are required before strong conclusions can be drawn.
A distinct and well-characterized area of CoA biology concerns hereditary disorders caused by mutations in the enzymes of the CoA biosynthetic pathway. While these are disease states rather than applications of supplementation in healthy people, they illuminate the critical importance of CoA levels in neurological health and have directly motivated research into CoA-restoration therapies.
Pantothenate kinase-associated neurodegeneration (PKAN), an inborn error of coenzyme A (CoA) metabolism, represents the most common form of neurodegeneration with brain iron accumulation (NBIA). This rare neurodegenerative disorder involves progressive extrapyramidal dysfunction (e.g., dystonia, rigidity, choreoathetosis), iron accumulation in the basal ganglia, and axonal spheroids within the central nervous system.
PKAN is a rare autosomal recessive disorder that largely affects children and young adults. The disease results from mutations in the pantothenate kinase gene (PANK2), which encodes the first enzyme in the biosynthesis of coenzyme A (CoA) from pantothenic acid (vitamin B5).
Deficient pantothenate kinase 2 is predicted to result in coenzyme A (CoA) depletion and defective membrane biosynthesis in those tissues in which this is the major pantothenate kinase or in tissues with the greatest CoA demand. Rod photoreceptors continually generate membranous discs; therefore, the retinopathy frequently observed in classic PKAN may be secondary to this deficit. The biochemical perturbations leading to clinical sequelae are still not completely understood and require further investigation.
Researchers generated induced pluripotent stem cells from PKAN patients and showed that their derived neurons exhibited premature death, increased ROS production, mitochondrial dysfunctions — including impairment of mitochondrial iron-dependent biosynthesis — and major membrane excitability defects. CoA supplementation prevented neuronal death and ROS formation by restoring mitochondrial and neuronal functionality. These findings provide direct evidence that PANK2 malfunctioning is responsible for abnormal phenotypes in human neuronal cells and indicate CoA treatment as a possible therapeutic intervention.
The discovery that mutations in COASY — the last enzyme in CoA biosynthesis — lead to a disorder with clinical features partially overlapping with those of PKAN confirmed the central role of CoA-dependent biochemistry in selected forms of neurodegeneration. CoPAN (COASY protein-associated neurodegeneration) is a very rare, autosomic recessive disorder characterized by early onset, mild oro-mandibular dystonia, dysarthria, spastic paraparesis, obsessive-compulsive behavior, and cognitive impairment.
The idea is that, by administering additional 4′-PPT to PKAN patients, their deficiency of CoA is compensated. In PKAN animal models, 4′-PPT was indeed found to have a beneficial effect. In September 2021, a clinical trial was started with 10 Dutch and Belgian PKAN patients. The general consensus that cells obtain their Coenzyme A via a de novo biosynthesis pathway starting with the uptake of vitamin B5 is challenged by work demonstrating that cells and organisms can take up Coenzyme A from external sources. The presence of alternative routes towards intracellular Coenzyme A is of high importance for subjects suffering from inborn genetic errors of impaired Coenzyme A de novo biosynthesis, resulting in severe neurodegenerative and cardiac diseases.
Evidence strength: The evidence linking CoA biosynthesis defects to specific neurodegenerative disorders is genetically robust and mechanistically well-characterized. However, therapeutic application of CoA or its precursors to restore brain CoA levels in these disorders remains in early-stage clinical investigation. Studies designed to support various PKAN therapeutic strategies have highlighted the intricacy of CoA metabolism and the limitations of our present understanding of disease causation. Improvements in our knowledge of the causes and therapy of PKAN may have ramifications for our comprehension of other, more prevalent diseases. As of recent review, no disease-modifying therapy for PKAN has received FDA approval; the currently accepted standard of care focuses on treating specific symptoms.
CoA and its primary thioester, acetyl-CoA, occupy a central position in cancer cell metabolism. This represents an active area of mechanistic research, though it does not yet translate into a clinical use-case for CoA supplementation in cancer treatment.
Acetyl-CoA is a vital metabolic intermediate involved in both anabolic and catabolic pathways. Its role extends to crucial physiological processes, such as glucose homeostasis and free fatty acid utilization. Moreover, acetyl-CoA plays a significant part in reshaping the metabolic microenvironment and influencing the progression of several diseases, including cancer, insulin resistance, diabetes, and heart failure.
In addition to its direct roles in metabolism, acetyl-CoA is used for protein modification via acetylation. Nutrient-sensitive histone acetylation has been linked to regulation of gene expression in different cell types, potentially impacting tumor progression. In cancer cells, acetyl-CoA availability for histone acetylation has been linked to gene expression related to lipid metabolism, proliferation, and invasive properties.
Perturbations of the biosynthesis and homeostasis of CoA and/or acyl-CoA are connected with several pathological conditions, including cancer, myopathies, and cardiomyopathies. Abnormal biosynthesis and homeostasis of CoA and its derivatives have been associated with various human pathologies, including cancer, diabetes, and neurodegeneration.
Evidence strength: The mechanistic links between CoA/acetyl-CoA availability and cancer metabolism are supported by substantial in vitro and animal research. This area is currently one of drug target discovery, not dietary supplementation. No clinical trials of CoA supplementation for cancer prevention or treatment in humans have been identified in the peer-reviewed literature.
Perturbations of the biosynthesis and homeostasis of CoA and/or acyl-CoA are connected with several pathological conditions, including myopathies and cardiomyopathies. In PPCS deficiency disorder (a rare CoA biosynthesis defect), research has shown cardiac involvement, and pantethine supplementation — which ultimately increases CoA precursor availability — has been studied to ameliorate dilated cardiomyopathy features.
Particular attention has been paid to the roles of changes in the level of CoA under pathological conditions, such as in neurodegenerative diseases, cancer, myopathies, and infectious diseases, and to the beneficial effect of CoA and pantethine (which, like CoA, is finally converted to pantothenate and cysteamine), used at pharmacological doses for the treatment of hyperlipidemia.
Evidence strength: Evidence for CoA's role in myopathies and cardiomyopathies is primarily mechanistic and derives from studies of rare genetic diseases. No clinical trials specifically testing CoA supplementation for these indications in non-genetic contexts were identified.
The following dosages are drawn directly from published clinical studies and registered clinical trials; they are not recommendations.
The unit-based dosing (200 U/d, 400 U/d) used in the Chinese lipid trials is specific to the Chinese pharmaceutical preparation of CoA capsules and does not correspond directly to a milligram mass dose in the same way as most Western supplements. The conversion between "units" and milligrams for this preparation has not been standardized in widely available published sources.
A fundamental pharmacological challenge for oral CoA supplementation is that CoA itself cannot diffuse across membranes, and each cell needs to take up pantothenate to synthesize its own CoA. This means that orally ingested CoA is not expected to be taken up intact by cells; the molecule must be broken down to pantothenate and other precursors in the gastrointestinal tract and blood, which are then used for de novo CoA biosynthesis intracellularly. The general consensus that cells obtain their Coenzyme A via a de novo biosynthesis pathway starting with the uptake of vitamin B5 is challenged by work demonstrating that cells and organisms can take up Coenzyme A from external sources, but this alternative uptake mechanism has not yet been definitively characterized or quantified in humans.
In the 8-week statin combination trial, the addition of CoA 400 U/d was effective, and the combination of CoA and statin was well tolerated. The trial reporting monotherapy for hypertriglyceridemia and the larger CoA-versus-fenofibrate trial similarly reported acceptable safety profiles in their Chinese study populations, though the full safety data from the fenofibrate comparison study are not accessible in open literature.
Much less is known about the importance of the concentration of CoA in various cell compartments and the role of altered CoA concentration in various pathologies. Despite continuous research on these issues, the molecular mechanisms in the regulation of the intracellular level of CoA under pathological conditions are still not well understood.
Abnormal biosynthesis and homeostasis of CoA and its derivatives have been associated with various human pathologies, including cancer, diabetes, and neurodegeneration. This bidirectional relationship — where both deficiency and dysregulation of CoA metabolism can be harmful — underscores that CoA homeostasis is tightly controlled and that simply adding more CoA precursor may not uniformly be beneficial across disease contexts.
Preclinical research has raised a signal of concern regarding CoA's immunomodulatory properties at supraphysiological concentrations. In primary bone marrow-derived macrophages, CoA supplementation alone (250–500 µM CoA) was sufficient to significantly upregulate transcript levels of the proinflammatory cytokines Il1b, Il1a, and Il6, as well as Nos2. Furthermore, CoA supplementation strongly synergized with LPS to enhance proinflammatory transcriptional output. Immunostimulatory effects of CoA also extended to naïve primary human myeloid cells, as CoA dose-dependently enhanced IL1B, IL1A, IL6, and TNF expression in donor monocytes either alone or in combination with LPS. These findings are from in vitro and cell-culture models and their relevance to oral supplementation in humans has not been established.
While all B vitamins function as critical cofactors or cofactor precursors in central metabolism, their dietary effects are not uniformly advantageous. Under certain conditions, they can produce unexpected and even adverse outcomes — for example, promoting leukemic cell proliferation. These findings underscore that our understanding of B vitamin metabolism in physiological and pathological states remains incomplete. The implication that augmenting CoA precursor supply could in some pathological contexts fuel tumor growth is an area requiring further investigation.
High oral doses of pantothenic acid or calcium pantothenate (≤10 g/day for several weeks) do not appear to be toxic to humans. This relates to the CoA precursor rather than CoA itself, but is relevant to supplementation strategies that aim to boost CoA indirectly through pantothenate loading.
No specific drug interaction data for oral CoA supplements have been identified in the peer-reviewed literature beyond the statin combination studies cited above, which reported tolerability. The combination studies explicitly assessed creatine phosphokinase (CPK) levels — a marker of muscle toxicity relevant when CoA is co-administered with statins — and the combination of CoA and statin had no significant effect on creatinine levels in this study. Interaction data outside the statin context are not available from the sources identified.
Condiciones de salud que Coenzima A puede ayudar a apoyar.
Coenzyme A (CoA) is the universal acyl-carrier essential for acetyl-CoA formation—the substrate that enters the TCA cycle for mitochondrial ATP synthesis—as well as for fatty acid beta-oxidation and amino acid catabolism. Its synthesis requires pantothenic acid (B5), and it is biochemically indispensable for all ATP-generating metabolic pathways.
Coenzyme A (CoA) is an essential cofactor in over 100 metabolic reactions, including the conversion of pyruvate to acetyl-CoA for TCA cycle entry and in fatty acid oxidation for energy production. It is biosynthesized from pantothenic acid (vitamin B5). CoA's direct role in cellular energy metabolism is scientifically well-established.
Coenzyme A (CoA) is an essential cofactor for cardiac energy metabolism, participating in over 100 metabolic reactions including fatty acid oxidation and the TCA cycle. Accumulating evidence identifies impaired CoA homeostasis as a pathomechanism in cardiac dysfunction and certain cardiomyopathies. Direct human evidence of CoA deficiency in cardiac disease emerged first in 2018, and recent research explores restoring CoA levels — via vitamin B5 and its derivatives — as a strategy to support heart function in affected patients.
Coenzyme A (CoA) is the universal acyl-group carrier in mitochondrial energy metabolism, essential for the conversion of pyruvate to acetyl-CoA, TCA cycle function, and fatty acid beta-oxidation. All three major macronutrient pathways (carbohydrate, fat, protein) must funnel through CoA to generate NADH/FADH₂ for the ETC.
Sistemas corporales que Coenzima A puede ayudar a apoyar.
Volver